Navigation Links
Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
Date:11/12/2009

NEWPORT, Ky., Nov. 12 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that the U.S. launch of Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules, is now underway and being supported by an expanded 250-member specialty sales force.

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor, a new treatment option for relief of mild to moderate acute pain in adults (18 years of age or older). With the national launch of Zipsor, Xanodyne has now successfully executed on two key elements of its business model - R&D and commercialization.

Commenting on the launch, Natasha Giordano, Chief Commercial Officer, said, "The launch of Zipsor was a tremendous achievement for Xanodyne. Within 90 days of receiving FDA approval, we were able to scale up our commercial organization and secure broad distribution at retail pharmacies for the product."

Giordano added, "This is an exciting time for Xanodyne as we seek to gain a foothold in the pain marketplace with Zipsor. Our newly expanded team of experienced sales representatives enables Xanodyne to achieve a greater geographic reach and frequency of product details to healthcare professionals across the United States."

Xanodyne remains committed to aggressively executing its product commercialization strategy for its emerging product portfolio. The Company expects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamic acid compound under priority review for the potential treatment of women suffering from heavy menstrual bleeding.

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of prescription pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

SOURCE Xanodyne Pharmaceuticals, Inc.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):